AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...

AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

Imfinzi in combination with chemotherapy has been recommended for approval in the European Union for the treatment of ...

AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for ...

This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...

The phase 3 NIAGARA trial randomised 1,063 MIBC patients to receive Imfinzi plus neoadjuvant chemotherapy prior to bladder ...

and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi ® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”). Several subjects from Phase 1 who received the ...

AstraZeneca Pharma India Ltd has received the nod from the Central Drugs Standard Control Organisation (CDSCO) to import and ...

AstraZeneca Pharma India has announced that the Company has received permission from the CentralDrugs Standard Control ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

AstraZeneca Pharma India receives CDSCO approval to import and distribute cancer treatment medicine Durvalumab solutions in ...